After Alnylam (ALNY) CEO Yvonne Greenstreet presented at the JPMorgan Healthcare Conference, JPMorgan thinks the Street will “continue to debate to some degree exactly how/where Amvuttra will be used in ATTR-CM,” but believes today’s positive stock reaction “makes sense” given the company’s above-consensus preliminary FY24 net product revenue outlook and 2025 guidance. The firm maintains a Neutral rating on Alnylam shares despite stating that it sees Alnylam “boasting an attractive platform and portfolio.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam reports preliminary FY24 product revenues $1.646B, up 33% versus FY23
- Alnylam price target lowered to $310 from $314 at Bernstein
- TransMedics names Gerardo Hernandez as CFO, succeeding Stephen Gordon
- FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatment
- Alnylam Pharmaceuticals announces interim Phase 1 data of nucresiran